

# Louise Emmett

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4739301/publications.pdf>

Version: 2024-02-01

95  
papers

5,791  
citations

125106

35  
h-index

87275

74  
g-index

97  
all docs

97  
docs citations

97  
times ranked

5308  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | <sup>177</sup> Lu-PSMA-617 and Idroneoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial. Journal of Nuclear Medicine, 2022, 63, 560-566.  | 2.8 | 22        |
| 2  | Defining radio-recurrent intra-prostatic target volumes using PSMA-targeted PET/CT and multi-parametric MRI. Clinical and Translational Radiation Oncology, 2022, 32, 41-47.   | 0.9 | 7         |
| 3  | Side effects of therapy with radiolabelled prostate specific membrane antigen (PSMA). , 2022, , .  |     | 0         |
| 4  | Primary tumour PSMA intensity is an independent prognostic biomarker for biochemical recurrence-free survival following radical prostatectomy. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3289-3294.  | 3.3 | 18        |
| 5  | High prostate-specific membrane antigen (PSMA) positron emission tomography (PET) maximum standardized uptake value in men with PI-RADS score 4 or 5 confers a high probability of significant prostate cancer. BJU International, 2022, 130, 5-7.   | 1.3 | 10        |
| 6  | All Prostate-specific Membrane Antigen Peptides Are Equal, but Some Are More Equal than Others. European Urology Oncology, 2022, 5, 283-284.   | 2.6 | 2         |
| 7  | Event-free survival after radical prostatectomy according to prostate-specific membrane antigen-positron emission tomography and European Association of Urology biochemical recurrence risk groups. BJU International, 2022, 130, 32-39.  | 1.3 | 11        |
| 8  | Metastasis-Free Survival and Patterns of Distant Metastatic Disease After Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET)-Guided Salvage Radiation Therapy in Recurrent or Persistent Prostate Cancer After Prostatectomy. International Journal of Radiation Oncology Biology Physics, 2022, 113, 1015-1024. | 0.4 | 18        |
| 9  | 18F-PSMA-11 as an Attractive 68Ga-PSMA-11 Alternative for Prostate Cancer Imaging. European Urology, 2022, , .   | 0.9 | 0         |
| 10 | Phase I/II Trial of the Combination of 177Lutetium Prostate specific Membrane Antigen 617 and Idroneoxil (NOX66) in Men with End-stage Metastatic Castration-resistant Prostate Cancer (LuPIN). European Urology Oncology, 2021, 4, 963-970.   | 2.6 | 27        |
| 11 | 68Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 477-482.  | 3.3 | 54        |
| 12 | Utilization of Salvage and Systemic Therapies for Recurrent Prostate Cancer as a Result of 18F-DCFPyL PET/CT Restaging. Advances in Radiation Oncology, 2021, 6, 100553.   | 0.6 | 7         |
| 13 | E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1626-1638.   | 3.3 | 188       |
| 14 | [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet, The, 2021, 397, 797-804.   | 6.3 | 552       |
| 15 | UpFrontPSMA: a randomized phase 2 study of sequential <sup>177</sup> Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naïve prostate cancer (clinical trial protocol). BJU International, 2021, 128, 331-342.  | 1.3 | 33        |
| 16 | Prostate-specific Membrane Antigen PET in Prostate Cancer. Radiology, 2021, 299, 248-260.  | 3.6 | 38        |
| 17 | Role of PSMA PET/CT imaging in the diagnosis, staging and restaging of prostate cancer. Future Oncology, 2021, 17, 2225-2241.  | 1.1 | 14        |
| 18 | ENZA-1 trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901). BJU International, 2021, 128, 642-651.  | 1.3 | 18        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Dual-Tracer Positron-Emission Tomography Using Prostate-Specific Membrane Antigen and Fluorodeoxyglucose for Staging of Prostate Cancer: A Systematic Review. <i>Advances in Urology</i> , 2021, 2021, 1-9.   | 0.6 | 13        |
| 20 | External Validation and Addition of Prostate-specific Membrane Antigen Positron Emission Tomography to the Most Frequently Used Nomograms for the Prediction of Pelvic Lymph-node Metastases: an International Multicenter Study. <i>European Urology</i> , 2021, 80, 234-242.  | 0.9 | 35        |
| 21 | The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study. <i>European Urology</i> , 2021, 80, 682-689.  | 0.9 | 181       |
| 22 | Qualitative study of nuclear medicine physicians' perceptions of positron emission tomography/computed tomography in pregnant patients with cancer. <i>Internal Medicine Journal</i> , 2021, 51, 1722-1726.   | 0.5 | 3         |
| 23 | Editorial Comment. <i>Journal of Urology</i> , 2021, , 101097JU000000000000225401.  | 0.2 | 0         |
| 24 | 3-Year Freedom from Progression After <sup>68</sup> Ga-PSMA PET/CTâ€“Triaged Management in Men with Biochemical Recurrence After Radical Prostatectomy: Results of a Prospective Multicenter Trial. <i>Journal of Nuclear Medicine</i> , 2020, 61, 866-872.   | 2.8 | 86        |
| 25 | Use of galliumâ€68 prostateâ€specific membrane antigen positronâ€emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature. <i>BJU International</i> , 2020, 125, 206-214.   | 1.3 | 80        |
| 26 | A Prospective Study of 18F-DCFPyL PSMA PET/CT Restaging in Recurrent Prostate Cancer following Primary External Beam Radiotherapy or Brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 546-555.  | 0.4 | 42        |
| 27 | Changing the Goal Posts: Prostate-specific Membrane Antigen Targeted Theranostics in Prostate Cancer. <i>Seminars in Oncology Nursing</i> , 2020, 36, 151052.   | 0.7 | 3         |
| 28 | Staging 18F-FDG PET/CT influences the treatment plan in melanoma patients with satellite or in-transit metastases. <i>Melanoma Research</i> , 2020, 30, 358-363.  | 0.6 | 14        |
| 29 | Clinical impact of PET imaging in prostate cancer management. <i>Current Opinion in Urology</i> , 2020, Publish Ahead of Print, 649-653.  | 0.9 | 1         |
| 30 | Prospective evaluation of the impact of human papilloma virus status and small node size on the diagnostic accuracy of 18F â€fluorodeoxyglucose positron emission tomography/computed tomography for primary head and neck squamous cell carcinoma. <i>ANZ Journal of Surgery</i> , 2020, 90, 1396-1401.  | 0.3 | 2         |
| 31 | Distribution of prostate cancer recurrences on galliumâ€68 prostateâ€specific membrane antigen ( <sup>68</sup> Gaâ€PSMA) positronâ€emission/computed tomography after radical prostatectomy with pathological nodeâ€positive extended lymph node dissection. <i>BJU International</i> , 2020, 125, 876-883.   | 1.3 | 10        |
| 32 | Protocol for the PRIMARY clinical trial, a prospective, multicentre, crossâ€sectional study of the additive diagnostic value of galliumâ€68 prostateâ€specific membrane antigen positronâ€emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer. <i>BJU International</i> , 2020, 125, 515-524.            | 1.3 | 51        |
| 33 | TheraP: A randomised phase II trial of <sup>177</sup> Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel: Initial results (ANZUP protocol 1603).. <i>Journal of Clinical Oncology</i> , 2020, 38, 5500-5500.  | 0.8 | 58        |
| 34 | Editorial Comment. <i>Journal of Urology</i> , 2020, 203, 99-99.  | 0.2 | 0         |
| 35 | Galliumâ€68â€prostateâ€specific membrane antigen ( <sup>68</sup> Ga<sup>â€PSMA</sup>) positron emission tomography (PET)/computed tomography (CT) predicts complete biochemical response from radical prostatectomy and lymph node dissection in intermediateâ€and highâ€risk prostate cancer. <i>BJU International</i> , 2019, 124, 62-68.   | 1.3 | 53        |
| 36 | Diagnostic accuracy of <sup>68</sup> Gaâ€prostateâ€specific membrane antigen (<sup>PSMA</sup>) positronâ€emission tomography (<sup>PET</sup>) and multiparametric (mp)<sup>MRI</sup> to detect intermediateâ€grade intraâ€prostatic prostate cancer using wholeâ€mount pathology: impact of the addition of <sup>68</sup> Gaâ€<sup>PSMA PET</sup> to mp<sup>MRI</sup>. <i>BJU International</i> , 2019, 124, 42-49. | 1.3 | 80        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | Tumour Heterogeneity and Resistance to Therapy in Prostate Cancer: A Fundamental Limitation of Prostate-specific Membrane Antigen Theranostics or a Key Strength?. <i>European Urology</i> , 2019, 76, 479-481.   | 0.9 | 7         |
| 38 | TheraP: a randomized phase 2 trial of <sup>177</sup> Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol) Tj ETQq 0 0 0 rgB/Overlorb10 Tf 50   | 1.5 | 10        |
| 39 | Radiotherapy for node-positive prostate cancer: 2019 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group. <i>Radiotherapy and Oncology</i> , 2019, 140, 68-75.  | 0.3 | 20        |
| 40 | Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 961-971.  | 5.1 | 126       |
| 41 | The Contribution of Multiparametric Pelvic and Whole-Body MRI to Interpretation of <sup>18</sup> F-Fluoromethylcholine or <sup>68</sup> Ga-HBED-CC PSMA-11 PET/CT in Patients with Biochemical Failure After Radical Prostatectomy. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1253-1258.   | 2.8 | 24        |
| 42 | Assessment of <sup>68</sup> Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer. <i>JAMA Oncology</i> , 2019, 5, 856.   | 3.4 | 493       |
| 43 | Asymptomatic Prostate Cancer Brain Metastases on <sup>68</sup> Ga-PSMA PET/CT. <i>Clinical Nuclear Medicine</i> , 2019, 44, e382-e384.  | 0.7 | 14        |
| 44 | Exceptional Response to <sup>177</sup> Lutetium Prostate-Specific Membrane Antigen in Prostate Cancer Harboring DNA Repair Defects. <i>JCO Precision Oncology</i> , 2019, 3, 1-5.   | 1.5 | 10        |
| 45 | <sup>68</sup> Ga-HBEDD PSMA-11 PET/CT staging prior to radical prostatectomy in prostate cancer patients: Diagnostic and predictive value for the biochemical response to surgery. <i>British Journal of Radiology</i> , 2019, 92, 20180667.  | 1.0 | 16        |
| 46 | Prospective, Multisite, International Comparison of <sup>18</sup> F-Fluoromethylcholine PET/CT, Multiparametric MRI, and <sup>68</sup> Ga-HBED-CC PSMA-11 PET/CT in Men with High-Risk Features and Biochemical Failure After Radical Prostatectomy: Clinical Performance and Patient Outcomes. <i>Journal of Nuclear Medicine</i> , 2019, 60, 794-800. | 2.8 | 61        |
| 47 | Rapid Modulation of PSMA Expression by Androgen Deprivation: Serial <sup>68</sup> Ga-PSMA-11 PET in Men with Hormone-Sensitive and Castrate-Resistant Prostate Cancer Commencing Androgen Blockade. <i>Journal of Nuclear Medicine</i> , 2019, 60, 950-954.   | 2.8 | 133       |
| 48 | Results of a Prospective Phase 2 Pilot Trial of <sup>177</sup> Lu-PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 15-22.  | 0.9 | 131       |
| 49 | <sup>68</sup> Ga-PSMA-PET/CT staging prior to definitive radiation treatment for prostate cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 343-346.   | 0.7 | 30        |
| 50 | Reversible Suppression of Lymphoproliferation and Thrombocytopenia with Rapamycin in a Patient with Common Variable Immunodeficiency. <i>Journal of Clinical Immunology</i> , 2018, 38, 159-162.  | 2.0 | 3         |
| 51 | The Impact of <sup>68</sup> Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study. <i>Journal of Nuclear Medicine</i> , 2018, 59, 82-88.   | 2.8 | 281       |
| 52 | Delineating sites of failure following post-prostatectomy radiation treatment using <sup>68</sup> Ga-PSMA-PET. <i>Radiotherapy and Oncology</i> , 2018, 126, 244-248.   | 0.3 | 27        |
| 53 | Imaging Prostate Cancer With Prostate-Specific Membrane Antigen PET/CT and PET/MRI: Current and Future Applications. <i>American Journal of Roentgenology</i> , 2018, 211, 286-294.   | 1.0 | 25        |
| 54 | Radiotherapy for recurrent prostate cancer: 2018 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group. <i>Radiotherapy and Oncology</i> , 2018, 129, 377-386.  | 0.3 | 39        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | Prospective evaluation of <sup>68</sup> Gallium prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer. <i>BJU International</i> , 2017, 119, 209-215.  | 1.3 | 263       |
| 56 | <sup>68</sup> Ga-PSMA-11 PET/CT Interobserver Agreement for Prostate Cancer Assessments: An International Multicenter Prospective Study. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1617-1623.  | 2.8 | 111       |
| 57 | Fruzemide aids diagnostic interpretation of <sup>68</sup> Ga-PSMA positron emission tomography/CT in men with prostate cancer. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2017, 61, 739-744.  | 0.9 | 23        |
| 58 | Development of standardized image interpretation for <sup>68</sup> Ga-PSMA PET/CT to detect prostate cancer recurrent lesions. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1622-1635.   | 3.3 | 91        |
| 59 | Futility of imaging to stage melanoma patients with a positive sentinel lymph node. <i>Melanoma Research</i> , 2017, 27, 457-462.   | 0.6 | 15        |
| 60 | Initial multicentre experience of <sup>68</sup> gallium-PSMA PET/CT guided robot-assisted salvage lymphadenectomy: acceptable safety profile but oncological benefit appears limited. <i>BJU International</i> , 2017, 120, 673-681.  | 1.3 | 67        |
| 61 | Lutetium <sup>177</sup> PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy. <i>Journal of Medical Radiation Sciences</i> , 2017, 64, 52-60.  | 0.8 | 222       |
| 62 | Delineating biochemical failure with <sup>68</sup> Ga-PSMA-PET following definitive external beam radiation treatment for prostate cancer. <i>Radiotherapy and Oncology</i> , 2017, 122, 99-102.  | 0.3 | 38        |
| 63 | Treatment Outcomes from <sup>68</sup> Ga-PSMA PET/CT-Informed Salvage Radiation Treatment in Men with Rising PSA After Radical Prostatectomy: Prognostic Value of a Negative PSMA PET. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1972-1976.                                    | 2.8 | 149       |
| 64 | Impact of Patient Preparation on the Diagnostic Performance of <sup>18</sup> F-FDG PET in Cardiac Sarcoidosis. <i>Clinical Nuclear Medicine</i> , 2016, 41, e327-e339.  | 0.7 | 72        |
| 65 | SPECT-CT versus VQ versus CTPA for diagnosing pulmonary embolus and other lung pathology: Pre-existing lung disease should not be a contraindication. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2016, 60, 492-497.   | 0.9 | 21        |
| 66 | <sup>68</sup> Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment. <i>BJU International</i> , 2016, 117, 732-739.  | 1.3 | 239       |
| 67 | Schwannoma Showing Avid Uptake on <sup>68</sup> Ga-PSMA-HBED-CC PET/CT. <i>Clinical Nuclear Medicine</i> , 2016, 41, 703-704.   | 0.7 | 30        |
| 68 | Brown Adipose Tissue Exhibits a Glucose-Responsive Thermogenic Biorhythm in Humans. <i>Cell Metabolism</i> , 2016, 23, 602-609.   | 7.2 | 149       |
| 69 | Prognostic and Diagnostic Implications of Nonperfusion Data on SPECT Myocardial Perfusion Imaging. <i>Current Cardiovascular Imaging Reports</i> , 2015, 8, 1.  | 0.4 | 0         |
| 70 | Prospective Comparison of <sup>18</sup> F-Fluoromethylcholine Versus <sup>68</sup> Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1185-1190. | 2.8 | 516       |
| 71 | Granulomatous sarcoid aortitis: a serious complication of a well-known multisystem disease. <i>Lancet</i> , The, 2015, 385, 2014.   | 6.3 | 7         |
| 72 | Sentinel lymph node mapping for defining site and extent of elective radiotherapy management of regional nodes in Merkel cell carcinoma: A pilot case series. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2014, 58, 353-359.   | 0.9 | 7         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 73 | Comparative assessment of rest and post-stress left ventricular volumes and left ventricular ejection fraction on gated myocardial perfusion imaging (MPI) and echocardiography in patients with transient ischaemic dilation on adenosine MPI: Myocardial stunning or subendocardial hypoperfusion?. <i>Journal of Nuclear Cardiology</i> , 2012, 19, 735-742. | 1.4 | 30        |
| 74 | Hypophosphataemic Osteomalacia in Patients on Adefovir Dipivoxil. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, 468-473.  | 1.1 | 41        |
| 75 | Progressive Visual Loss Due to Obstruction of an Optic Nerve Sheath Fenestration Demonstrated on SPECT/CT Radionuclide Cisternography. <i>Clinical Nuclear Medicine</i> , 2010, 35, 208-210.  | 0.7 | 2         |
| 76 | Severe Ischaemia on SPECT Myocardial Perfusion Imaging Secondary to Microvascular Dysfunction and Apical Hypertrophic Cardiomyopathy. <i>Clinical Nuclear Medicine</i> , 2010, 35, 937-940.   | 0.7 | 2         |
| 77 | Effect of unilateral endobronchial valve insertion on pulmonary ventilation and perfusion: A pilot study. <i>Respirology</i> , 2010, 15, 1079-1083.   | 1.3 | 23        |
| 78 | Hypophosphatemic Osteomalacia after Low-Dose Adefovir Dipivoxil Therapy for Hepatitis B. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 479-480.   | 1.8 | 37        |
| 79 | Increased In-111 Octreotide Uptake due to Paget Disease and a Low Midline Pelvic Kidney. <i>Clinical Nuclear Medicine</i> , 2009, 34, 84-86.  | 0.7 | 2         |
| 80 | Hypertrophic Pulmonary Osteoarthropathy Demonstrated on SPECT/CT. <i>Clinical Nuclear Medicine</i> , 2009, 34, 628-631.   | 0.7 | 13        |
| 81 | Prospective evaluation of the impact of diabetes and left ventricular hypertrophy on the relationship between ischemia and transient ischemic dilation of the left ventricle on single-day adenosine Tc-99m myocardial perfusion imaging. <i>Journal of Nuclear Cardiology</i> , 2008, 15, 638-643.   | 1.4 | 18        |
| 82 | SPECT/CT of Femoroacetabular Impingement. <i>Clinical Nuclear Medicine</i> , 2008, 33, 757-762.   | 0.7 | 26        |
| 83 | Natural History of Right Ventricular Dysfunction After Acute Pulmonary Embolism. <i>Journal of the American Society of Echocardiography</i> , 2007, 20, 885-894.  | 1.2 | 37        |
| 84 | Atrial and Ventricular Echocardiographic Correlates of the Extent of Pulmonary Embolism in the Elderly. <i>Journal of the American Society of Echocardiography</i> , 2006, 19, 347-353.   | 1.2 | 25        |
| 85 | Electrocardiographic prediction of the severity of posterior wall perfusion defects on rest technetium-99m Sestamibi myocardial perfusion imaging. <i>Journal of Electrocardiology</i> , 2005, 38, 195-203.   | 0.4 | 1         |
| 86 | The role of left ventricular hypertrophy and diabetes in the presence of transient ischemic dilation of the left ventricle on myocardial perfusion SPECT images. <i>Journal of Nuclear Medicine</i> , 2005, 46, 1596-601.   | 2.8 | 34        |
| 87 | Rhabdomyolysis Resulting From Interaction of Simvastatin and Clarithromycin Demonstrated by Tc-99m MDP Scintigraphy. <i>Clinical Nuclear Medicine</i> , 2004, 29, 803-804.  | 0.7 | 24        |
| 88 | A Critical Appraisal of Pinhole Scintigraphy of the Ankle and Foot. <i>Clinical Nuclear Medicine</i> , 2002, 27, 707-710.   | 0.7 | 4         |
| 89 | Reversible regional wall motion abnormalities on exercise technetium-99m gated cardiac single photon emission computed tomography predict high-grade angiographic stenoses. <i>Journal of the American College of Cardiology</i> , 2002, 39, 991-998.   | 1.2 | 112       |
| 90 | SPET of a computerised model of diffuse lung disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2001, 28, 150-154.  | 2.2 | 4         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 91 | Paraspinal Abscess Complicating Facet Joint Injection. <i>Clinical Nuclear Medicine</i> , 2000, 25, 71.                     | 0.7 | 46        |
| 92 | Sequestered Collection in Association With Infected Arthroplasty. <i>Clinical Nuclear Medicine</i> , 2000, 25, 288-289.     | 0.7 | 1         |
| 93 | Sunburst Periosteal Reaction in a Bony Metastasis. <i>Clinical Nuclear Medicine</i> , 2000, 25, 392-393.                    | 0.7 | 2         |
| 94 | <i>Eikenella Corrodens</i> Vertebral Osteomyelitis. <i>Clinical Nuclear Medicine</i> , 2000, 25, 1059-1060.                 | 0.7 | 11        |
| 95 | Pain in the Anterior Pelvis and Postoperative Prostatectomy Findings. <i>Clinical Nuclear Medicine</i> , 1999, 24, 523-524. | 0.7 | 0         |